1. What is the Trust’s annual spend on anti-TNF drugs (most recent year available)?
2. How many patients has the Trust treated with anti-TNF drugs in the last 12 months?
3. What is the % split of anti-TNF patients by the following channels?
4. How many patients has the Trust treated with the following conditions in last 12 months?
5. Are there any gain share agreements in place between the Trust and CCGs for anti-TNF biosimilars?
If yes, please provide:
